ETR:SAZ - STADA Arzneimittel Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started €82.50 0.00 (0.00 %) (As of 07/22/2018 10:49 AM ET)Previous Close€82.50Today's Range€82.02 - €82.8052-Week Range€53.41 - €90.24Volume29,746 shsAverage Volume51,761 shsMarket Capitalization$5.27 billionP/E RatioN/ADividend Yield0.13%BetaN/A Company ProfileAnalyst RatingsHeadlinesChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. Receive SAZ News and Ratings via Email Sign-up to receive the latest news and ratings for SAZ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical SymbolETR:SAZ CUSIPN/A Webwww.stada.de Phone+49-6101-6030 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins3.48% Return on Equity7.58% Return on Assets2.27% Miscellaneous EmployeesN/A Outstanding Shares62,260,000Market Cap$5,270.00 STADA Arzneimittel (ETR:SAZ) Frequently Asked Questions What is STADA Arzneimittel's stock symbol? STADA Arzneimittel trades on the ETR under the ticker symbol "SAZ." What price target have analysts set for SAZ? 6 brokers have issued 1-year target prices for STADA Arzneimittel's shares. Their predictions range from €66.25 to €89.00. On average, they expect STADA Arzneimittel's stock price to reach €74.74 in the next year. This suggests that the stock has a possible downside of 9.4%. View Analyst Ratings for STADA Arzneimittel. What is the consensus analysts' recommendation for STADA Arzneimittel? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STADA Arzneimittel in the last year. There are currently 5 sell ratings and 1 hold rating for the stock, resulting in a consensus recommendation of "Sell." Who are some of STADA Arzneimittel's key competitors? Some companies that are related to STADA Arzneimittel include MERCK KGAA/S (MKKGY), Merck KGaA (MRK), Valeant Pharmaceuticals Intl (VRX), Canopy Growth (WEED), Aurora Cannabis (ACB), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ) and OrganiGram (OGRMF). Who are STADA Arzneimittel's key executives? STADA Arzneimittel's management team includes the folowing people: Dr. Claudio Albrecht, Chairman of the Exec. Board & CEO (Age 59)Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)Ms. Leslie Isabelle Iltgen, VP of Investor RelationsMr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43) Has STADA Arzneimittel been receiving favorable news coverage? News articles about SAZ stock have trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. STADA Arzneimittel earned a media sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 44.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. What is STADA Arzneimittel's stock price today? One share of SAZ stock can currently be purchased for approximately €82.50. How big of a company is STADA Arzneimittel? STADA Arzneimittel has a market capitalization of $5.27 billion. How can I contact STADA Arzneimittel? STADA Arzneimittel's mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The company can be reached via phone at +49-6101-6030. MarketBeat Community Rating for STADA Arzneimittel (ETR SAZ)Community Ranking: 1.7 out of 5 ()Outperform Votes: 67 (Vote Outperform)Underperform Votes: 128 (Vote Underperform)Total Votes: 195MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimittel and other stocks. Vote "Outperform" if you believe SAZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?